Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Off-Year Scheme Drifting Away from Four-Minister Deal: JPMA Exec
July 19, 2024
- Cancel or Postpone FY2025 Revision, or Scrap Off-Year Scheme: New JPA Chief
July 19, 2024
- FIRM Hails Guidance on Conditional Approval of Regenerative Medicines
July 17, 2024
- EFPIA Japan Names Yoshiaki Aono as Director General
July 11, 2024
- Labor Union Group Urges Abolishment of Off-Year Price Revisions
June 27, 2024
- Japan Digital Health Alliance Keen to Boost Ties with Overseas Organizations
June 21, 2024
- JGA to Establish Study Group on Generic Industry Realignment
June 21, 2024
- Majority of Candidates for G1 Withdrawal Scheme Not Able to Exit Market: FPMAJ Survey
June 17, 2024
- FPMAJ Hails 2024 Reform, but Frets No Mention of Scrapping Off-Year Cuts in Honebuto Draft
June 17, 2024
- EFPIA Japan Issues New Proposal on HTA, Calls for Transparency
June 10, 2024
- 135 Meds Still in Lag/Loss State in Japan, JPMA Task Force Revving Up Fight
June 5, 2024
- JPMA Pushing Industry-Academia Consortia in Non-Competitive Drug Discovery Fields
June 5, 2024
- JPMA, PhRMA, EFPIA to Jointly Survey Views on 2024 Drug Pricing Reform
May 24, 2024
- New Task Force Discussing Steps to Stem Further Increase in Drug Lag/Loss: JPMA
April 30, 2024
- JPMA Eager to Work with Regulators to Improve Guidance on Orphan Meds, PI Trials
April 30, 2024
- Policymakers Prod for Industry’s Concrete Actions Toward Eliminating Drug Loss
April 24, 2024
- Govt Should Buy Up Domestic Antibiotic APIs, Cost 5-8 Times Higher: Industry Official
April 24, 2024
- JPMA Reiterates Opposition to Off-Year Revisions towards Honebuto 2024
April 19, 2024
- Doctors’ Lobby Objects MOF Proposal for CEA Use in Reimbursement Decisions
April 18, 2024
- Only 3 Prefectures Log “Below 80%” Generic Rate in November: Kyokai Kenpo
April 10, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…